This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06901349 |
|---|---|
| Status | Withdrawn |
| Phase | Phase 2 |
| Sponsor | Eli Lilly and Company |
| Enrollment | Not stated |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity; Overweight |
| Interventions | Bimagrumab; Tirzepatide; Bimagrumab Placebo; Tirzepatide Placebo |
| Start | May 23, 2025 |
| Primary completion | Jun 10, 2025 |
| Study completion | Jun 10, 2025 |
| Results posted | Not yet |
| Registry last updated | Sep 24, 2025 |
Compounds on this site that cite this trial
What the registry says the trial is about
The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 36 |
15 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
